Newsletter Tool

Today's Rundown

UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis
Ready to eat: Investors fork out $76M for Pheast's cancer therapies
Sponsored: Using Knowledge Graphs to Drive Drug Discovery
Pfizer-Valneva's Lyme disease vaccine performs even better in children
UPDATE: Trevena's COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning
Another setback for Axsome as migraine med expected to get a no from FDA
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China
Hope for stroke? Protein could limit damage by shielding parts of brain
Medtronic finds new medical, scientific chief in current research and regulatory leader Mauri
US to increase availability of Pfizer's Paxlovid even as demand remains spotty
AHA: Federal funds needed to offset 20% per-patient increase in hospital expenses since 2019

Trending Topic: Cell & Gene Therapy
Read on to understand how the industry is addressing gene therapy and cell therapy research and development.

Featured Story

UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends

By Max Bayer

Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends

Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis

By Nick Paul Taylor

Protagonist Therapeutics has failed to persuade investors of its take on a phase 2 ulcerative colitis trial. While Protagonist made the case that the low dose was a big success, investors picked out the failure of the high dose as the key finding and sent the stock spiraling downward.

Ready to eat: Investors fork out $76M for Pheast's cancer therapies

By Gabrielle Masson

Investors have an appetite for Pheast. The women-led immuno-oncology startup just closed out a $76 million series A funding round, fueled its development therapies targeting cancer's “don’t eat me” signal.

Pfizer and Valneva’s Lyme disease vaccine worked even better in children than adults, leading the partners to add this population to a late-stage test beginning in the third quarter.

UPDATE: Trevena's COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning

By Max Bayer

Enrollment for Trevena’s COVID-19 treatment trial, part of the National Institutes of Health’s ACTIV-4 program, has ceased after the program’s data safety monitoring board found that the company’s med reached an “inferiority stopping criterion.”

Another setback for Axsome as migraine med expected to get a no from FDA

By Max Bayer

Axsome Therapeutics is bracing for another setback as the FDA is now expected to nix an application for its migraine med due to unresolved manufacturing issues.

Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder

By Gabrielle Masson

Amid chaos comes good news—Editas Medicine has received Rare Pediatric Disease designation from the FDA for its gene-edited medicine EDIT-301 to treat beta thalassemia.

Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China

By Annalee Armstrong

Arrowhead and Vivo Capital are forming a new company called Visirna Therapeutics to take four of the biotech’s RNAi therapies to China, with an initial investment of $60 million from the venture capital firm to get going.

Hope for stroke? Protein could limit damage by shielding parts of brain

By Gabrielle Masson

Scientists have discovered a protein interaction that may protect areas of the brain from stroke’s second wave of damage and could serve as a potential drug target for improving outcomes in humans.

Medtronic finds new medical, scientific chief in current research and regulatory leader Mauri

By Andrea Park

To replace Richard Kuntz, its outgoing chief medical and scientific officer, Medtronic looked inward.

US to increase availability of Pfizer's Paxlovid even as demand remains spotty

By Kevin Dunleavy

Pfizer's COVID-19 oral antiviral Paxlovid isn't exactly flying off the shelves of pharmacies these days. But the Biden administration still is taking steps to increase its availability. The U.S. is working with Pfizer to increase the manufacture and supply of the pills, an administration official told reporters on Monday.